I am a breastfeeding mother and i want to know if it is safe to use UNII-13T4O6VMAM? Is UNII-13T4O6VMAM safe for nursing mother and child? Does UNII-13T4O6VMAM extracts into breast milk? Does UNII-13T4O6VMAM has any long term or short term side effects on infants? Can UNII-13T4O6VMAM influence milk supply or can UNII-13T4O6VMAM decrease milk supply in lactating mothers?
- DrLact safety Score for UNII-13T4O6VMAM is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of UNII-13T4O6VMAM is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that UNII-13T4O6VMAM does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of UNII-13T4O6VMAM safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
It is excreted in breast milk in clinically non-significant amount and no problems have been observed in infants whose mothers took this medication. Levels in plasma and urine of such infants were undetectable. Having published less quantity of studies than with other drugs of the same group, safer alternatives may be preferable, especially in the neonatal period and in case of prematurity. The American Academy of Pediatrics rates it as usually compatible with breastfeeding.
Low amounts of UNII-13T4O6VMAM in milk and failure to detect UNII-13T4O6VMAM or its metabolites in the urine of 2 older infants indicates that it would not be expected to cause adverse effects in older breastfed infants. Because there is no published experience with UNII-13T4O6VMAM during breastfeeding in the newborn period, shorter-acting agents may be preferred while nursing a newborn or preterm infant.
No adverse effects were found in the breastfed infant of a patient receiving 20 mg of UNII-13T4O6VMAM daily for 4 months starting the 9th month postpartum.Four infants 3 to 4.5 months of age remained healthy during long-term therapy of their mothers with UNII-13T4O6VMAM 20 mg daily.
: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.